Clinical Trial Update: Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating MORAb-003 (farletuzumab) for women with ovarian cancer that relapsed after platinum-based chemotherapy has completed, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Neoplasms

Drugs mentioned

• MORAb-003 (farletuzumab)

Snippet

Sponsor: Morphotek | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-02-15